GBA1 and Parkinson disease: The enzymatic nucleophile of GBA was identified (and corrected from Asp443[19]) by the Wither's lab through covalent‐trapping of the enzyme with a 2‐fluoro‐2‐deoxy glucoside inactivator.[20] Given the clinical importance of GBA in both GD and PD, it is arguably the most widely studied human glucosidase, with relentless interest in developing novel chaperones,[21, 22, 23, 24] inhibitors[25, 26, 27] and activity‐based probes (ABPs)[28, 29] to study this enzyme in disease pathogenesis, diagnosis and treatment.